Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

Completed

• Conditions: Colorectal Neoplasms
• Interventions: Other: Serum proteomics

• Registration Number: NCT01604798
• Lead Sponsor: Fudan University

Brief Summary

No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Therefore, it is urgent that accurate and reliable serum biomarkers be identified.

Detailed Description

Magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen serum samples from CRC patients and healthy controls.

Study Timeline

• Study Start: 2007-01
• Status Verified: 2012-05
• Primary Completion: 2012-05
• Study Completion: 2012-05
• Study First Submitted: 2012-05-17
• Study First Submitted QC: 2012-05-22
• Last Update Submitted: 2012-05-22
• Study First Posted: 2012-05-24
• Last Update Posted: 2012-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 547

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Healthy Controls	Serum proteomics	Healthy volunteers
Colorectal Cancer Patients	Serum proteomics	Patients with histologically confirmed colorectal cancer

Primary Outcome Measures

Name	Time	Method
Serum peptide mass fingerprinting (PMF)	2010.03-2012.05 (2 years)	Compare PMF of the colorectal caner group and control group, and then build the model to distinguish patients with colorectal cancer and controls

Secondary Outcome Measures

Name	Time	Method
Expressed peptide peaks	2010.03-2012.05 (2 years)	Find differentially expressed peptide peaks from the model and identify some ideal serum biomarkers for the early diagnosis of colorectal cancer

Trial Locations

Locations (1)

Zhongshan Hospital, Fudan University; 🇨🇳 Shanghai, Shanghai, China